Alto Neuroscience (Alto Neuroscience) FCF Yield % : -1.63 (As of May. 16, 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Alto Neuroscience's Trailing 12-Month Free Cash Flow is $-6.08 Mil, and Market Cap is $372.07 Mil. Therefore, Alto Neuroscience's FCF Yield % for today is -1.63%.

The historical rank and industry rank for Alto Neuroscience's FCF Yield % or its related term are showing as below:

ANRO' s FCF Yield % Range Over the Past 10 Years
Min: -1.76 Med: 0 Max: 0
Current: -1.63

ANRO's FCF Yield % is ranked better than
80.33% of 1556 companies
in the Biotechnology industry
Industry Median: -14.305 vs ANRO: -1.63

Alto Neuroscience's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Alto Neuroscience FCF Yield % Historical Data

The historical data trend for Alto Neuroscience's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience FCF Yield % Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
FCF Yield %	-	-	-	-	-

Competitive Comparison of Alto Neuroscience's FCF Yield %

For the Biotechnology subindustry, Alto Neuroscience's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alto Neuroscience's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alto Neuroscience's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Alto Neuroscience's FCF Yield % falls into.

Alto Neuroscience FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Alto Neuroscience's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-33.918	/	0
	=	N/A%

Alto Neuroscience's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	0	*	4	/	0
	=	N/A%

Alto Neuroscience FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Alto Neuroscience FCF Yield % Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024